Scarica l'app Stockscreener
9.11
0.33%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Precedente Chiudi:
$9.14
Aprire:
$9.16
Volume 24 ore:
1.94M
Relative Volume:
1.20
Capitalizzazione di mercato:
$570.47M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
-1.0858
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-1.73%
1M Prestazione:
-0.22%
6M Prestazione:
+28.67%
1 anno Prestazione:
-25.14%
Intervallo 1D:
$9.10
$9.17
Intervallo di 1 settimana:
$9.10
$9.235
Portata 52W:
$4.62
$13.47
Sage Therapeutics Inc Stock (SAGE) Company Profile
Nome
Sage Therapeutics Inc
Settore
Industria
Telefono
617-299-8380
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta SAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
9.11 | 580.51M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-11 | Ripresa | BofA Securities | Underperform |
| 2024-11-21 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Iniziato | Citigroup | Sell |
| 2024-05-29 | Iniziato | Robert W. Baird | Neutral |
| 2024-04-17 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-08-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-08 | Downgrade | Needham | Buy → Hold |
| 2023-08-07 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-08-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Downgrade | Stifel | Buy → Hold |
| 2023-08-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-03-31 | Iniziato | Berenberg | Hold |
| 2021-11-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-16 | Downgrade | Citigroup | Buy → Neutral |
| 2021-04-07 | Iniziato | Piper Sandler | Overweight |
| 2021-02-26 | Downgrade | Mizuho | Buy → Neutral |
| 2021-02-25 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Ripresa | Raymond James | Mkt Perform |
| 2021-01-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-01-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Reiterato | H.C. Wainwright | Neutral |
| 2020-09-11 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-08-10 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-04-08 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-28 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-06 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-12-05 | Reiterato | Guggenheim | Buy |
| 2019-12-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-10-30 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-23 | Iniziato | Wedbush | Outperform |
| 2019-04-25 | Iniziato | Jefferies | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Sage Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Jammu Links News
Is Sage Therapeutics Inc. a good long term investmentSuperior profit margins - Jammu Links News
Sage Therapeutics (NASDAQ:SAGE) Stock Price Passes Above 50 Day Moving AverageTime to Sell? - MarketBeat
What analysts say about Sage Therapeutics Inc. stockDynamic profit expansion - Jammu Links News
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World
Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com
Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq
SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus
Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener
Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance
Sage to lay off most staff amid Supernus buyout - BioPharma Dive
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO - Stock Titan
Canaccord Genuity Group Issues Positive Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Needham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar
SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus
Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus
Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):